Galectin Therapeutics

Company snapshot

Galectin Therapeutics (NASDAQ: GALT) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on the Company’s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function. We use naturally occurring carbohydrate polymers with galactose residues to create

• 12 active pipeline program(s) linked via ClinicalTrials.gov.
• 20 US patent(s) indexed to this assignee profile.
• 12 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Galectin Therapeutics. Not investment advice.

• Peer + 0 momentum

  IO Biotech

  TA overlap score 33.2

• Peer + 0 momentum

  Bristol Myers Squibb

  TA overlap score 28

• Peer + 0 momentum

  Iovance Biotherapeutics

  TA overlap score 27.2

• Peer + 0 momentum

  Madrigal Pharmaceuticals EU

  TA overlap score 23.2

• Peer + 0 momentum

  Galmed Pharmaceuticals

  TA overlap score 22.6

• Peer + 0 momentum

  Provectus Biopharmaceuticals

  TA overlap score 22.4

Recent activity

Latest pipeline, patent, and corporate events for Galectin Therapeutics.

1. Jun 8, 2026 Clinical update

   GR-MD-02 — Phase 1

2. Jun 5, 2026 Clinical update

   Placebo of BELAPECTIN, BELAPECTIN — Phase 3

3. Jun 5, 2026 Clinical update

   GR-MD-02 — Phase 2

4. Jun 5, 2026 Clinical update

   GR-MD-02 — Phase 1

5. Jun 5, 2026 Clinical update

   belapectin — Phase 3

View all clinical trial activity →

• What is Galectin Therapeutics?

  Galectin Therapeutics is a pharma organization headquartered in Norcross, USA. It trades on NYSE under ticker GALT. Primary therapeutic focus areas include Colorectal Cancer, Esophageal Varices in NASH Cirrhosis, Metastatic Melanoma, Hepatic Impairment, Prevention of Esophageal V

• Is Galectin Therapeutics publicly traded?

  Yes. Galectin Therapeutics is listed with ticker GALT on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Galectin Therapeutics develop or market?

  We link 5 drug profile(s) where Galectin Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/galectin-therapeutics-inc#company-drugs.

• What are the latest developments for Galectin Therapeutics?

  In the last 12 months our linked public records show 12 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does Galectin Therapeutics focus on?

  Galectin Therapeutics focuses on Colorectal Cancer, Esophageal Varices in NASH Cirrhosis, Metastatic Melanoma based on our analysis of their pipeline programs and drug development activities.